2025 · 1st Quarter (Jan 1 - Mar 31)
Filed by PLASMA PROTEIN THERAPEUTICS ASSOCIATION.
Open official filingSource-reported fields
Expense method: A
Literal source text
Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Literal federal measure citations: HR 6465
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Literal federal measure citations: HR 3808
Issues relating to tariffs and the importation of plasma-derived medicines, plasma intermediates, and materials necessary to collect source plasma donations and manufacture plasma derived-medicines.
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
